Quantcast
Home > Quotes > SIGA

SIGA Technologies Inc. Common Stock (SIGA) Quote & Summary Data

SIGA 
$5.64
*  
0.06
1.08%
Get SIGA Alerts
*Delayed - data as of Nov. 19, 2018  -  Find a broker to begin trading SIGA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    SIGA Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 5.85 / $ 5.49
Share Volume
215,937
50 Day Avg. Daily Volume
206,947
Previous Close
$ 5.58
52 Week High / Low
$ 8.47 / $ 4.68
Market Cap
446,462,727
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
215,937
50 Day Avg. Daily Volume:
206,947

Trading Range

The current last sale of $5.64 is 20.51% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 5.85 $ 8.47
 Low: $ 5.49 $ 4.68

Company Description (as filed with the SEC)

SIGA Technologies, Inc. is referred to throughout this report as "SIGA," "the Company," "we" or "us." We are a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, an orally administered antiviral drug for the treatment of human smallpox disease caused by variola virus. A new drug application ("NDA") for TPOXX® was submitted to the United States Food & Drug Administration ("FDA") in December 2017. In February 2018, the Company received notice that the FDA granted priority review of the NDA and that the FDA's target final action date is August 8, 2018. While TPOXX® is not yet approved as safe or effective by the FDA, it is a novel small-molecule drug that is being delivered to the U.S.  ... More ...  

Nasdaq Official Price

Open Price:
$ 5.66
Open Date:
Nov. 19, 2018
Close Price:
$ 5.64
Close Date:
Nov. 19, 2018

Research Brokers before you trade

Want to trade FX?

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x